KR910002670B1 - 아모술랄롤 하이드로클로라이드 지속성 제제의 제조방법 - Google Patents

아모술랄롤 하이드로클로라이드 지속성 제제의 제조방법 Download PDF

Info

Publication number
KR910002670B1
KR910002670B1 KR1019840005306A KR840005306A KR910002670B1 KR 910002670 B1 KR910002670 B1 KR 910002670B1 KR 1019840005306 A KR1019840005306 A KR 1019840005306A KR 840005306 A KR840005306 A KR 840005306A KR 910002670 B1 KR910002670 B1 KR 910002670B1
Authority
KR
South Korea
Prior art keywords
hydrochloride
amosulrolol
mixture
amosulolol
enteric material
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
KR1019840005306A
Other languages
English (en)
Korean (ko)
Other versions
KR850001693A (ko
Inventor
다까시 소노베
히로시 수기우라
도모오 이또오
마사요시 아루가
히로이츄 카와타
Original Assignee
야마노우치세이야쿠카부시키가이샤
모리오까 시게오
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 야마노우치세이야쿠카부시키가이샤, 모리오까 시게오 filed Critical 야마노우치세이야쿠카부시키가이샤
Publication of KR850001693A publication Critical patent/KR850001693A/ko
Application granted granted Critical
Publication of KR910002670B1 publication Critical patent/KR910002670B1/ko
Expired legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1019840005306A 1983-08-31 1984-08-30 아모술랄롤 하이드로클로라이드 지속성 제제의 제조방법 Expired KR910002670B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP58-160086 1983-08-31
JP160086 1983-08-31
JP58160086A JPS6051106A (ja) 1983-08-31 1983-08-31 塩酸アモスラロ−ル持続性製剤

Publications (2)

Publication Number Publication Date
KR850001693A KR850001693A (ko) 1985-04-01
KR910002670B1 true KR910002670B1 (ko) 1991-05-03

Family

ID=15707557

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019840005306A Expired KR910002670B1 (ko) 1983-08-31 1984-08-30 아모술랄롤 하이드로클로라이드 지속성 제제의 제조방법

Country Status (7)

Country Link
US (2) US4724148A (enExample)
EP (1) EP0136103B1 (enExample)
JP (1) JPS6051106A (enExample)
KR (1) KR910002670B1 (enExample)
AT (1) ATE57833T1 (enExample)
DE (1) DE3483504D1 (enExample)
ES (1) ES8602406A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20140005173A (ko) * 2011-02-25 2014-01-14 레놀리트 에스이 표면방오방법

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6051106A (ja) * 1983-08-31 1985-03-22 Yamanouchi Pharmaceut Co Ltd 塩酸アモスラロ−ル持続性製剤
GB8724763D0 (en) * 1987-10-22 1987-11-25 Aps Research Ltd Sustained-release formulations
US5258186A (en) * 1989-03-10 1993-11-02 Yamanouchi Pharmaceutical Co., Ltd. Drug release controlling coating material for long acting formulations
ATE124864T1 (de) * 1989-03-10 1995-07-15 Yamanouchi Pharma Co Ltd Die wirkstoffabgabe steuerndes überzugsmaterial für lang wirksame formulierungen.
EP0447168A3 (en) * 1990-03-16 1993-01-07 Yamanouchi Pharmaceutical Co. Ltd. Long acting granular pharmaceutical composition
US5523289A (en) * 1991-04-15 1996-06-04 Abbott Laboratories Pharmaceutical composition
WO1992020326A1 (en) * 1991-05-20 1992-11-26 Marion Laboratories, Inc. Multi-layered controlled release formulation
EP0642789B1 (en) * 1992-05-22 1999-09-29 Senju Pharmaceutical Co., Ltd. Remedy for glaucoma
FR2737494B1 (fr) * 1995-08-04 1997-08-29 Synthelabo Derives de benzenesulfonamide, leur preparation et leur application en therapeutique
US5773031A (en) * 1996-02-27 1998-06-30 L. Perrigo Company Acetaminophen sustained-release formulation
MXPA00010805A (es) * 1998-05-06 2002-05-08 Univ Duke Metodo para el tratamiento de sindromes de la vejiga y del tracto urinario inferior.
US6383511B1 (en) * 1999-10-25 2002-05-07 Epicept Corporation Local prevention or amelioration of pain from surgically closed wounds
AU1169601A (en) * 1999-11-16 2001-05-30 Ranbaxy Laboratories Limited Taste masked oral compositions
JP4494712B2 (ja) * 2002-11-12 2010-06-30 大日本住友製薬株式会社 マルチプルユニット型徐放性製剤
US20050215561A1 (en) * 2004-03-19 2005-09-29 Krishnendu Ghosh Pharmaceutical dosage forms and compositions
DE102006020604A1 (de) * 2006-05-02 2007-11-08 Bayer Healthcare Ag Flüssige Arzneimittelformulierung
US9072670B2 (en) 2007-10-19 2015-07-07 Otsuka Pharmaceutical Co., Ltd. Matrix-type pharmaceutical solid preparation
CA2936740C (en) 2014-10-31 2017-10-10 Purdue Pharma Methods and compositions particularly for treatment of attention deficit disorder
US11491114B2 (en) * 2016-10-12 2022-11-08 Curioralrx, Llc Formulations for enteric delivery of therapeutic agents
US10722473B2 (en) 2018-11-19 2020-07-28 Purdue Pharma L.P. Methods and compositions particularly for treatment of attention deficit disorder

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT270071B (de) * 1966-08-12 1969-04-10 Roehm & Haas Gmbh Dragierlack für Arzneiformen
US3538214A (en) * 1969-04-22 1970-11-03 Merck & Co Inc Controlled release medicinal tablets
DE2010416B2 (de) * 1970-03-05 1979-03-29 Hoechst Ag, 6000 Frankfurt Oral anwendbare Arzneiform mit Retardwirkung
DE2031871C3 (de) * 1970-06-27 1974-06-27 Roehm Gmbh, 6100 Darmstadt Überzugsmasse für Arzneiformen
US3784683A (en) * 1971-03-29 1974-01-08 Abbott Lab Tablet preparation
US3954959A (en) * 1973-03-28 1976-05-04 A/S Alfred Benzon Oral drug preparations
DE2336218C3 (de) * 1973-07-17 1985-11-14 Byk Gulden Lomberg Chemische Fabrik Gmbh, 7750 Konstanz Orale Arzneiform
JPS535728B2 (enExample) * 1974-01-12 1978-03-01
GB1568837A (en) * 1975-10-10 1980-06-04 Squibb & Sons Inc Controlled release tablet
CA1147342A (en) * 1977-10-12 1983-05-31 Kazuo Imai Process of producing novel phenylethanolamine derivatives
DD146547A5 (de) * 1978-07-15 1981-02-18 Boehringer Sohn Ingelheim Arzneimittel-retardform mit unloeslichen poroesen diffusionshuellen
US4289750A (en) * 1978-10-16 1981-09-15 Kopp Klaus F Therapy of conditions which may be associated with altered renal function and dosage forms therefor
JPS606330B2 (ja) * 1978-11-30 1985-02-18 山之内製薬株式会社 α・β両遮断剤
DE3000979A1 (de) * 1980-01-12 1981-07-23 Dr. Karl Thomae Gmbh, 7950 Biberach Neue dipyridamol-retardformen und verfahren zu ihrer herstellung
DE3124090A1 (de) * 1981-06-19 1983-01-05 Dr. Karl Thomae Gmbh, 7950 Biberach Neue orale dipyridamolformen
DE3126703A1 (de) * 1981-07-07 1983-01-27 Dr. Karl Thomae Gmbh, 7950 Biberach Bromhexin-retardform und verfahren zu ihrer herstellung
JPS6051106A (ja) * 1983-08-31 1985-03-22 Yamanouchi Pharmaceut Co Ltd 塩酸アモスラロ−ル持続性製剤

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20140005173A (ko) * 2011-02-25 2014-01-14 레놀리트 에스이 표면방오방법

Also Published As

Publication number Publication date
ATE57833T1 (de) 1990-11-15
DE3483504D1 (de) 1990-12-06
KR850001693A (ko) 1985-04-01
JPS6051106A (ja) 1985-03-22
US4765988A (en) 1988-08-23
US4724148A (en) 1988-02-09
JPH0443049B2 (enExample) 1992-07-15
ES535545A0 (es) 1985-12-01
EP0136103B1 (en) 1990-10-31
ES8602406A1 (es) 1985-12-01
EP0136103A2 (en) 1985-04-03
EP0136103A3 (en) 1986-10-22

Similar Documents

Publication Publication Date Title
KR910002670B1 (ko) 아모술랄롤 하이드로클로라이드 지속성 제제의 제조방법
US4309404A (en) Sustained release pharmaceutical compositions
CA1147650A (en) Sustained release pharmaceutical compositions
US6117453A (en) Solid compositions containing polyethylene oxide and an active ingredient
US4309406A (en) Sustained release pharmaceutical compositions
US4248856A (en) Sustained release pharmaceutical compositions
CA1147649A (en) Sustained release pharmaceutical compositions
JP5282722B2 (ja) ナテグリニド含有製剤
EP0386967B1 (en) A drug-release controlling coating material for long acting formulations
JP2608183B2 (ja) ピモベンダン経口投与製剤
US6048547A (en) Process for manufacturing solid compositions containing polyethylene oxide and an active ingredient
KR20010074914A (ko) 오메프라졸 제형
WO1999062499A1 (en) Stabilized pharmaceutical compositions
JPH0733330B2 (ja) 弾性被膜を有する安定な固形調剤及びその製造方法
EP0571973B1 (en) Slow-release sodium valproate tablets
JP3110794B2 (ja) １，４−ジヒドロピリジン誘導体を含有する製剤
KR0133526B1 (ko) Nb-818의 용이흡수성 약제
EP0410422A2 (en) A highly absorbable pharmaceutical composition
KR100515201B1 (ko) 라세미화반응에대하여안정화된실란세트론제제
JPH04234812A (ja) 持続性製剤用顆粒
EP0121901B1 (en) Ph independent controlled releasable tablets
JPH11335302A (ja) 安定な医薬組成物
EP0447168A2 (en) Long acting granular pharmaceutical composition
CA1231894A (en) Process of producing long acting formulations of amosulalol hydrochloride
KR100540037B1 (ko) 펠로디핀의 지속성 정제 및 그 제조방법

Legal Events

Date Code Title Description
PA0109 Patent application

St.27 status event code: A-0-1-A10-A12-nap-PA0109

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

G160 Decision to publish patent application
PG1605 Publication of application before grant of patent

St.27 status event code: A-2-2-Q10-Q13-nap-PG1605

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U11-oth-PR1002

Fee payment year number: 1

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 19940504

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 19940504

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R13-asn-PN2301

St.27 status event code: A-5-5-R10-R11-asn-PN2301